NDC 52709-1601-03: RAGWITEK AMBROSIA ARTEMISIIFOLIA POLLEN 12 [Amb'a'1'U]/1 Tablet, Carton of 30
This is a package of 30 tablets of RAGWITEK AMBROSIA ARTEMISIIFOLIA POLLEN 12 [Amb'a'1'U]/1 Tablet from ALK-Abello A S, no longer marketed (first marketed Apr 2014), no longer in the FDA NDC Directory; retail pharmacies pay about $11.75 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 52709-1601-3 alone.
- Record
- FDA NDC Directory package listing · Standardized allergenic
- Code segments
- 52709 labeler · 1601 product · 3 package
- Package marketed since
- Apr 17, 2014
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Billing quantity
- 30 EA per package
- Barcode (UPC-A, from the NDC)
- 3 5270916013 5
- Medicaid fills, this package
- 132 prescriptions in the last four reported quarters
- FDA record last changed
- Aug 6, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 072266
- GCN: 36402
- GPI-14 (Medi-Span): 20100060200720
- HICL (First Databank): 041079
- AHFS class code: 80:02.00.00
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $11.749 | $352.47 / 30 tablets |
| Medicaid paysCMS SDUD · 12 mo | $11.74 | $352.29 / 30 tablets |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file · file of Nov 18, 2026
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 52709-1601-03 You're viewing this Main listing | 3 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK Inner NDC 52709-1601-1 · each blister pack (10 tablets) | $11.75 / ea | $352.47 | 2014-04-17 | — | Inactivated by FDA |
| 52709-1601-05 52709-1601-5 | 1 BLISTER PACK in 1 CARTON / 5 TABLET in 1 BLISTER PACK | — | — | 2014-04-17 | — | Inactivated by FDA |
In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 52709-1601-05?
What NDC number is used to bill for this package of RAGWITEK AMBROSIA ARTEMISIIFOLIA POLLEN 12 [Amb'a'1'U]/1 Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Ragwitek 12 [Amb'a'1'U]this 52709-1601-03 | ALK-Abello | 30 tablets | $11.749 | — | Discontinued | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file · file of Nov 18, 2026
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.
🛈 What do these terms mean?
- Biologic patent
- A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
- Reference-product exclusivity
- A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
- Interchangeable exclusivity
- The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
- Earliest biosimilar (LOE)
- The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.
Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.
| Code | What it grants | Expires |
|---|---|---|
| RefProduct | Reference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this date | Apr 17, 2026 |
Is there a biosimilar for RAGWITEK SUBLINGUAL TABLET?
Why do different websites show different biosimilar dates?
Can a biosimilar launch before the last patent expires?
What does “current Purple Book estimate” mean?
What does “FDA listed” mean?
What does a patent or protection date mean here?
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 3OWL53L36A
A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
-
UNII 8JC99XGU4W
Soluble fish skin collagen is a protein derived from fish skin that acts as a binder and thickening agent in medicines. It helps hold ingredients together and gives the product the right texture or consistency.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
3 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from ALK-Abello A S labeler code 52709
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
🚨 Boxed Warning ▾
WARNING: SEVERE ALLERGIC REACTIONS ● RAGWITEK can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction. ( 5.1 ) ● Do not administer RAGWITEK to patients with severe, unstable or uncontrolled asthma. ( 4 ) ● Observe patients in the office for at least 30 minutes following the initial dose.
( 5.1 ) ● Prescribe auto-injectable epinephrine, instruct and train patients or parents/guardians on its appropriate use, and instruct patients or parents/guardians to seek immediate medical care upon its use. ( 5.2 ) ● RAGWITEK may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction. ( 5.2 ) ● RAGWITEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.
( 5.2 ) WARNING: SEVERE ALLERGIC REACTIONS See full prescribing information for complete boxed warning. • RAGWITEK can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction . ( 5.1 ) • Do not administer RAGWITEK to patients with severe, unstable or uncontrolled asthma . ( 4 ) • Observe patients in the office for at least 30 minutes following the initial dose.
( 5.1 ) • Prescribe auto-injectable epinephrine, instruct and train patients or parents/guardians on its appropriate use, and instruct patients or parents/guardians to seek immediate medical care upon its use. ( 5.2 ) • RAGWITEK may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction. ( 5.2 ) • RAGWITEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.
( 5.2 )
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE RAGWITEK ® is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in persons 5 through 65 years of age. RAGWITEK is not indicated for the immediate relief of allergic symptoms.
RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in persons 5 through 65 years of age. ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION For sublingual use only. For sublingual use only. One tablet daily.
( 2.1 ) Initiate treatment at least 12 weeks before the expected onset of ragweed pollen season and continue treatment throughout the season. ( 2.2 ) Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved.
Do not swallow for at least 1 minute. ( 2.2 ) Administer the first dose of RAGWITEK under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases. Observe patients in the office for at least 30 minutes following the initial dose.
( 2.2 )
2.1Dos e One RAGWITEK tablet daily. 2. 2 Administration Administer the first dose of RAGWITEK in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases.
After receiving the first dose of RAGWITEK, observe the patient for at least 30 minutes to monitor for signs or symptoms of a severe systemic or a severe local allergic reaction. If the patient tolerates the first dose, the patient may take subsequent doses at home. Take the tablet from the blister unit after carefully removing the foil with dry hands.
Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute.
Wash hands after handling the tablet. Do not take the tablet with food or beverage. Food or beverage should not be taken for the following 5 minutes after taking the tablet.
Initiate treatment at least 12 weeks before the expected onset of ragweed pollen season and continue treatment throughout the season. The safety and efficacy of initiating treatment in season have not been established. Data regarding the safety of restarting treatment after missing a dose of RAGWITEK are limited.
In the clinical trials, treatment interruptions for up to seven days were allowed. Prescribe auto-injectable epinephrine to patients prescribed RAGWITEK and instruct them (or their parents/guardians) in the proper use of auto-injectable epinephrine [see Warnings and Precautions ( 5.2 )] .
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS RAGWITEK is available as 12 Amb a 1-Unit (Amb a 1-U) tablets that are white to off-white, circular with a debossed double hexagon on one side. Tablet, 12 Amb a 1-Unit (Amb a 1-U) ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS RAGWITEK is contraindicated in patients with: Severe, unstable or uncontrolled asthma A history of any severe systemic allergic reaction A history of any severe local reaction after taking any sublingual allergen immunotherapy A history of eosinophilic esophagitis Hypersensitivity to any of the inactive ingredients [gelatin, mannitol, and sodium hydroxide] contained in this product [see Description ( 11 )]. Severe, unstable or uncontrolled asthma. ( 4 ) History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy.
( 4 ) A history of eosinophilic esophagitis. ( 4 ) Hypersensitivity to any of the inactive ingredients contained in this product. ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Inform patients or parents/guardians of the signs and symptoms of serious allergic reactions and instruct them to seek immediate medical care and discontinue therapy should any of these occur. ( 5.1 ) In case of oral inflammation or wounds, stop treatment with RAGWITEK to allow complete healing of the oral cavity. ( 5. 7 )
5.1Severe Allergic Reactions RAGWITEK can cause systemic allergic reactions including anaphylaxis which may be life-threatening. In addition, RAGWITEK can cause severe local reactions, including laryngopharyngeal swelling, which can compromise breathing and be life-threatening. Allergic reactions may require treatment with epinephrine.
Prescribe auto-injectable epinephrine to patients receiving RAGWITEK. Instruct patients or parents/guardians to recognize the signs and symptoms of a severe allergic reaction and in the proper use of auto-injectable epinephrine. Instruct patients or parents/guardians to seek immediate medical care and to stop treatment with RAGWITEK upon use of auto-injectable epinephrine [see Patient Counseling Information ( 17 )] .
See Prescribing Information for epinephrine for complete information. RAGWITEK may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious allergic reaction or that may increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function (either chronic or acute); severe mast cell disorder; or cardiovascular disease including unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension.
In addition, RAGWITEK may not be suitable for patients who are taking medications that can potentiate or inhibit the effects of epinephrine (see Prescribing Information for epinephrine for information on drug interactions). Administer the initial dose of RAGWITEK in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases and prepared to manage a life-threatening systemic or local allergic reaction. Observe patients in the office for at least 30 minutes following the initial dose of RAGWITEK.
5. 2 Upper Airway Compromise RAGWITEK can cause local reactions in the mouth or throat that could compromise the upper airway [see Adverse Reactions ( 6.1 )] . Consider discontinuation of RAGWITEK in patients who experience persistent and escalating adverse reactions in the mouth or throat.
5. 3 Eosinophilic Esophagitis Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy [see Contraindications ( 4 )] . Discontinue RAGWITEK and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastro-esophageal symptoms including dysphagia or chest pain.
5. 4 Asthma Subjects with asthma who participated in clinical trials had asthma of a severity that required, at most, a daily medium dose of an inhaled corticosteroid. RAGWITEK has not been studied in subjects with severe asthma.
Withhold immunotherapy with RAGWITEK if the patient is experiencing an acute asthma exacerbation. Reevaluate patients who have recurrent asthma exacerbations and consider discontinuation of RAGWITEK. 5.
5 Concomitant Allergen Immunotherapy RAGWITEK has not been studied in subjects who are receiving concomitant allergen immunotherapy. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy. 5.
6 Oral Inflammation Stop treatment with RAGWITEK to allow complete healing of the oral cavity in patients with oral inflammation (e.g., oral lichen planus, mouth ulcers, or thrush) or oral wounds, such as those following oral surgery or dental extraction.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS Adverse reactions reported in ≥5% of adults were: throat irritation, oral pruritus, ear pruritus, oral paresthesia, mouth edema, and tongue pruritus. Adverse reactions reported in ≥5% of children and adolescents 5 through 17 years of age were: throat irritation, oral pruritus, ear pruritus, lip swelling, glossodynia, nausea, oral pain, pharyngeal edema, swollen tongue, abdominal pain upper, stomatitis, and enlarged uvula. Adverse reactions reported in ≥5% of adults were: throat irritation, oral pruritus, ear pruritus, oral paresthesia, mouth edema, and tongue pruritus.
Adverse reactions reported in ≥5% of children and adolescents 5 through 17 years of age were: throat irritation, oral pruritus, ear pruritus, lip swelling, glossodynia, nausea, oral pain, pharyngeal edema, swollen tongue, abdominal pain upper, stomatitis, and enlarged uvula. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact ALK-Abelló Inc., a subsidiary of ALK-Abelló A/S, at 1-855-216-6497 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice . Adults In 4 placebo-controlled clinical trials, 1057 subjects 18 years of age and older with short ragweed pollen-induced rhinitis, with or without conjunctivitis, received at least one dose of RAGWITEK, of whom 327 (31%) completed at least 12 weeks of therapy.
Of the subjects treated with RAGWITEK, 52% were male, 25% had mild asthma, and 82% were sensitized to other allergens in addition to ragweed pollen. The subject population was 83% White, 12% African American, and 2% Asian. Subject demographics in placebo-treated subjects were similar to the active group.
The pooled analysis includes safety data from two 28-day safety studies and safety data from the first 28 days of two 52-week safety and efficacy studies. Adverse reactions reported in ≥1% of subjects in the 28-day pooled analysis treated with RAGWITEK are shown in Table 1. The most common adverse reactions reported in subjects treated with RAGWITEK were throat irritation (16.6% vs 3.3% placebo), oral pruritus (10.9% vs 2.0%), ear pruritus (10.4% vs 1.1%), and oral paresthesia (10.0% vs 4.0%).
The percentage of subjects who discontinued from the clinical trials because of an adverse reaction while exposed to RAGWITEK or placebo was 4.4% and 0.8%, respectively. The most common adverse reactions that led to study discontinuation in subjects who were exposed to RAGWITEK were mouth edema, swollen tongue, and dysphagia. One subject (1/1057; 0.1%) who received RAGWITEK experienced a treatment-related severe systemic allergic reaction that led to discontinuation of RAGWITEK.
The subject had local reactions starting on Day 1 of treatment with RAGWITEK. On Day 6 symptoms progressed and included swelling of the throat, dyspnea, nausea, and lightheadedness. The subject fully recovered after treatment with epinephrine (self-administered), antihistamines, and oral corticosteroids.
Table 1: Adverse Reactions Reported in ≥1% of Adults Treated with RAGWITEK or Placebo (28-day pooled analysis) Adverse Reaction RAGWITEK (N=1057) Placebo (N=757) Ear and Labyrinth Disorders Ear pruritus 10.4% 1.1% Respiratory, Thoracic and Mediastinal Disorders Throat irritation Oropharyngeal pain Throat tightness 16.6% 1.5% 1.3% 3.3% 0.7% 0.5% Gastrointestinal Disorders Oral pruritus Paresthesia oral Mouth edema Tongue pruritus Lip swelling Swollen tongue Lip pruritus Dry mouth Tongue edema Nausea Palatal edema Dysphagia 10.9% 10.0% 6.1% 5.1% 3.0% 2.9% 1.5% 1.4% 1.3% 1.1% 1.1% 1.0% 2.0% 4.0% 0.5% 0.5% 0.4% 0.5% 0.1% 0.7% 0.5% 0.3% 0% 0% Skin and Subcutaneous Tissue Disorders Pruritus 1.8% 1.3% General Disorders and Administration Site C onditions Chest discomfort 1.0% 0% * 1036 subjec… [Excerpted — this section continues on DailyMed.]
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available human data do not establish the presence or absence of RAGWITEK-associated risks during pregnancy.
In an embryo/fetal developmental toxicity study, RAGWITEK subcutaneously administered to mice during gestation at doses up to approximately 3 times the human sublingual dose did not reveal adverse developmental outcomes in fetuses (see
8.1Data) . Data Animal Data In a developmental toxicity study, the effect of RAGWITEK on embryo/fetal development was evaluated in mice. Animals were administered RAGWITEK subcutaneously daily from day 6 to day 15 of the gestation period at doses approximately 1 to 3 times the human sublingual dose of 12 Amb a 1-U.
There were no RAGWITEK-related post-implantation losses, fetal malformations or variations. 8. 2 Lactation Risk Summary It is not known whether RAGWITEK is excreted in human milk.
Data are not available to assess the effects of RAGWITEK on the breastfed child or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for RAGWITEK and any potential adverse effects on the breastfed child from RAGWITEK or from the underlying maternal condition.
8.4Pediatric Use Efficacy and safety of RAGWITEK have been established in children and adolescents 5 through 17 years of age. The efficacy and safety in pediatric patients below 5 years of age have not been established.
8.5Geriatric Use RAGWITEK is not approved for use in patients over 65 years of age because safety and efficacy have not been established.
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available human data do not establish the presence or absence of RAGWITEK-associated risks during pregnancy.
In an embryo/fetal developmental toxicity study, RAGWITEK subcutaneously administered to mice during gestation at doses up to approximately 3 times the human sublingual dose did not reveal adverse developmental outcomes in fetuses (see
8.1Data) . Data Animal Data In a developmental toxicity study, the effect of RAGWITEK on embryo/fetal development was evaluated in mice. Animals were administered RAGWITEK subcutaneously daily from day 6 to day 15 of the gestation period at doses approximately 1 to 3 times the human sublingual dose of 12 Amb a 1-U. There were no RAGWITEK-related post-implantation losses, fetal malformations or variations.
🧒 Pediatric Use ▾
8.4Pediatric Use Efficacy and safety of RAGWITEK have been established in children and adolescents 5 through 17 years of age. The efficacy and safety in pediatric patients below 5 years of age have not been established.
🧓 Geriatric Use ▾
8.5Geriatric Use RAGWITEK is not approved for use in patients over 65 years of age because safety and efficacy have not been established.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action The precise mechanisms of action of allergen immunotherapy are not known.
🧬 Mechanism of Action ▾
12.1Mechanism of Action The precise mechanisms of action of allergen immunotherapy are not known.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING RAGWITEK 12 Amb a 1-U tablets are white to off-white, circular sublingual tablets with a debossed double hexagon on one side. RAGWITEK is supplied as follows: 3 blister packages of 10 tablets (30 tablets total). NDC 52709-1601-3 Store at controlled room temperature, 20ºC to 25ºC (68ºF to 77ºF); excursions permitted between 15ºC to 30ºC (59ºF to 86ºF). Store in the original package until use to protect from moisture.
📋 Description ▾
11 DESCRIPTION RAGWITEK tablets contain pollen allergen extract from Short Ragweed ( Ambrosia artemisiifolia ). RAGWITEK is a sublingual tablet that dissolves within 10 seconds. RAGWITEK is available as a tablet of 12 Amb a 1-U of short ragweed pollen allergen extract. Inactive ingredients: gelatin NF (fish source), mannitol USP, and sodium hydroxide NF.
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise patients or parents/guardians to read the FDA-approved patient labeling ( Medication Guide ) and to keep RAGWITEK and all medicines out of the reach of children. Severe Allergic Reactions Advise patients or parents/guardians that RAGWITEK may cause life-threatening systemic or local allergic reactions, including anaphylaxis. Educate patients or parents/guardians about the signs and symptoms of these allergic reactions [see Warnings and Precautions ( 5.1 )] .
The signs and symptoms of a severe allergic reaction may include: syncope, dizziness, hypotension, tachycardia, dyspnea, wheezing, bronchospasm, chest discomfort, cough, abdominal pain, vomiting, diarrhea, rash, pruritus, flushing, and urticaria. Ensure that patients (or their parents/guardians) have auto-injectable epinephrine and instruct patients or parents/guardians in its proper use. Instruct patients (or their parents/guardians) who experience a severe allergic reaction to seek immediate medical care, discontinue RAGWITEK, and resume treatment only when advised by a physician to do so [ s ee Warnings and Precautions ( 5.1 )] .
Advise patients or parents/guardians to read the patient information for epinephrine. Inform patients or parents/guardians that the first dose of RAGWITEK must be administered in a healthcare setting under the supervision of a physician and that they will be monitored for at least 30 minutes to watch for signs and symptoms of life-threatening systemic or local allergic reaction [see Warnings and Precautions ( 5.1 )] . Because of the risk of upper airway compromise, instruct patients (or their parents/guardians) with persistent and escalating adverse reactions in the mouth or throat to discontinue RAGWITEK and to contact their healthcare professional [ s ee Warnings and Precautions ( 5.2 )] .
Because of the risk of eosinophilic esophagitis, instruct patients (or their parents/guardians) with severe or persistent symptoms of esophagitis to discontinue RAGWITEK and to contact their healthcare professional [ s ee Warnings and Precautions ( 5.3 )] . Asthma Instruct patients (or their parents/guardians) with asthma that if they have difficulty breathing or if their asthma becomes difficult to control, they should stop taking RAGWITEK and contact their healthcare professional immediately [see Warnings and Precautions ( 5.4 )] .
Administration Instructions Instruct patients (or their parents/guardians) to carefully remove the foil from the blister unit with dry hands and then take the sublingual tablet immediately by placing it under the tongue where it will dissolve. Also instruct patients (or their parents/guardians) to wash their hands after handling the tablet, and to avoid food or beverages for 5 minutes after taking the tablet [ s ee Dosage and Administration ( 2.2 )] . Manufactured for: ALK-Abelló A/S ALK-Abelló A/S, Bøge Allé 6-8, DK-2970 Hørsholm, Denmark U.S.
License No. 1292 Manufactured by: Catalent Pharma Solutions Limited, Blagrove, Swindon, Wiltshire, SN5 8RU UK Copyright © 2022 ALK-Abelló A/S. All rights reserved.
💬 Medication Guide ▾
MEDICATION GUIDE RAGWITEK ® (RAG-wi-tek) (Short Ragweed Pollen Allergen Extract) Carefully read this Medication Guide before you or your child start taking RAGWITEK ® and each time you get a refill. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment. Talk with your doctor or pharmacist if there is something you do not understand or if you want to learn more about RAGWITEK.
What is the Most Important Information I Should Know about RAGWITEK? RAGWITEK can cause severe allergic reactions that may be life-threatening. Stop taking RAGWITEK and get medical treatment right away if you or your child have any of the following symptoms after taking RAGWITEK: Trouble breathing Throat tightness or swelling Trouble swallowing or speaking Dizziness or fainting Rapid or weak heartbeat Severe stomach cramps or pain, vomiting, or diarrhea Severe flushing or itching of the skin For home administration of RAGWITEK, your doctor will prescribe auto-injectable epinephrine, a medicine you can inject if you or your child have a severe allergic reaction after taking RAGWITEK.
Your doctor will train and instruct you on the proper use of auto-injectable epinephrine. Talk to your doctor or read the epinephrine patient information if you have any questions about the use of auto-injectable epinephrine. What is RAGWITEK ?
RAGWITEK is a prescription medicine used for sublingual (under the tongue) immunotherapy to treat ragweed pollen allergies that can cause sneezing, runny or itchy nose, stuffy or congested nose, or itchy and watery eyes. RAGWITEK may be prescribed for persons 5 through 65 years of age who are allergic to ragweed pollen. RAGWITEK is taken for about 12 weeks before ragweed pollen season and throughout ragweed pollen season.
RAGWITEK is NOT a medication that gives immediate relief for symptoms of ragweed allergy. RAGWITEK is not approved for use in children younger than 5 years of age or in adults older than 65 years of age. Who Should Not Take RAGWITEK?
You or your child should not take RAGWITEK if: You or your child have severe, unstable or uncontrolled asthma You or your child had a severe allergic reaction in the past that included any of these symptoms: ○ Trouble breathing ○ Dizziness or fainting ○ Rapid or weak heartbeat You or your child have ever had difficulty with breathing due to swelling of the throat or upper airway after using any sublingual immunotherapy before. You or your child have ever been diagnosed with eosinophilic esophagitis. You or your child are allergic to any of the inactive ingredients contained in RAGWITEK.
The inactive ingredients contained in RAGWITEK are: gelatin, mannitol, and sodium hydroxide. What Should I Tell My Doctor Before Taking RAGWITEK? Your doctor may decide that RAGWITEK is not the best treatment if: You or your child have asthma, depending on how severe it is.
You or your child suffer from lung disease such as chronic obstructive pulmonary disease (COPD) You or your child suffer from heart disease such as coronary artery disease, an irregular heart rhythm, or you have hypertension that is not well controlled. You or your daughter are pregnant, plan to become pregnant during the time you will be taking RAGWITEK, or are breast-feeding. You or your child are unable or unwilling to administer auto-injectable epinephrine to treat a severe allergic reaction to RAGWITEK.
You or your child are taking certain medicines that enhance the likelihood of a severe reaction, or interfere with the treatment of a severe reaction. These medicines include: ○ beta blockers and alpha-blockers (prescribed for high blood pressure) ○ cardiac glycosides (prescribed for heart failure or problems with heart rhythm) ○ diuretics (prescribed for heart conditions and high blood pressure) ○ ergot alkaloids (prescribed for migraine headache) ○ monoamine oxidase inhibitors or tricyclic antidepressants (prescribed for depression) ○ thyroid hormone (prescribed for low… [Excerpted — this section continues on DailyMed.]
🔬 Clinical Studies ▾
14 CLINICAL STUDIES Adults The efficacy of RAGWITEK in the treatment of ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, was investigated in two double-blind, placebo-controlled clinical trials in adults 18 through 50 years of age. Subjects received RAGWITEK or placebo for approximately 12 weeks prior to the start of the ragweed pollen season and throughout the ragweed pollen season. The subject population was 86% White, 9% African American, and 3% Asian.
The subject population was almost equally divided between males and females. Overall, the mean age of subjects was 36 years. Subjects with asthma who participated in clinical trials had asthma of a severity that required, at most, a daily low dose of an inhaled corticosteroid.
Approximately 16% of subjects had mild asthma at baseline. Efficacy was established by self-reporting of rhinoconjunctivitis daily symptom scores (DSS) and daily medication scores (DMS). Daily rhinoconjunctivitis symptoms included four nasal symptoms (runny nose, stuffy nose, sneezing, and itchy nose), and two ocular symptoms (gritty/itchy eyes and watery eyes).
The rhinoconjunctivitis symptoms were measured on a scale of 0 (none) to 3 (severe). Subjects in clinical trials were allowed to take symptom-relieving medications (including systemic and topical antihistamines, and topical and oral corticosteroids) as needed. The daily medication score measured the use of standard open-label allergy medications.
Predefined values were assigned to each class of medication. Generally, systemic and topical antihistamines were given the lowest score, topical steroids an intermediate score, and oral corticosteroids the highest score. The sums of the DSS and DMS were combined into the Total Combined Score (TCS) which was averaged over the peak ragweed pollen season.
Also, in each study, the average TCS over the entire ragweed season was assessed. Other endpoints in both studies included the average DSS during the peak and entire ragweed season, and the average DMS during the peak ragweed season. Trial 1 The first study was a placebo-controlled trial which evaluated subjects 18 through 50 years of age comparing RAGWITEK (n=187) and placebo (n=188) administered as a sublingual tablet daily.
In this trial, approximately 22% of subjects had mild asthma and 85% were sensitized to other allergens in addition to short ragweed. Subjects with asthma who participated in this trial had asthma of a severity that required, at most, a daily low dose of an inhaled corticosteroid. Subjects with a clinical history of symptomatic allergies to non-short ragweed pollen allergens that required treatment during the ragweed pollen season were excluded from the trial.
The subject population was 78% White, 12% African American, and 8% Asian, and almost equally divided between males and females. The mean age of subjects in this study was 35.4 years. The two treatment groups were balanced with regard to baseline characteristics.
The results of this study are shown in Table 4. Trial 2 The second study was a placebo-controlled trial which evaluated subjects 18 through 50 years of age comparing RAGWITEK (n=194) and placebo (n=198) administered as a sublingual tablet daily. Approximately 17% of subjects had mild asthma and 78% were sensitized to other allergens in addition to short ragweed.
Subjects with asthma who participated in this trial had asthma of a severity that required, at most, a daily low dose of an inhaled corticosteroid. Subjects with a clinical history of symptomatic allergies to non-short ragweed pollen allergens that required treatment during the ragweed pollen season were excluded from the trial. The subject population was 88% White, 8.9% African American, 2% Asian, and almost equally divided between males and females.
The mean age of subjects in this study was 36.4 years. The two treatment groups were balanced with regard to baseline characteristics. The results of this study are shown in Table 5.
A dec… [Excerpted — this section continues on DailyMed.]
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been performed in animals to evaluate the carcinogenic potential of RAGWITEK . There were no positive findings in a combined in vivo Comet and micronucleus assay in rats using Short Ragweed ( Ambrosia artemisiifolia ) pollen allergen extract. Fertility studies have not been performed with Short Ragweed pollen allergen extract.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been performed in animals to evaluate the carcinogenic potential of RAGWITEK . There were no positive findings in a combined in vivo Comet and micronucleus assay in rats using Short Ragweed ( Ambrosia artemisiifolia ) pollen allergen extract. Fertility studies have not been performed with Short Ragweed pollen allergen extract.
📄 Recent Major Changes ▾
Indications and Usage ( 1 ) 04/2021
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL NDC 52709-1601-3 This carton contains 30 sublingual tablets in three 10-Tablet blister cards Short R agweed Pollen Allergen Extract, Ragwitek ® Tablet for sublingual use 12 Amb a 1-U For Persons 5 through 65 Years of Age Each Ragwitek tablet contains 12 Amb a 1-U of short ragweed pollen allergen extract. Dispense the enclosed Medication Guide to the patient. Keep this and all drugs out of the reach of children.
Rx only NDC 52709-1601-3 This carton contains 30 sublingual tablets in three 10-Tablet blister cards Short Ragweed Pollen Allergen Extract, Ragwitek® Tablet for sublingual use 12 Amb a 1-U For Persons 5 through 65 Years of Age Each Ragwitek tablet contains 12 Amb a 1-U of short ragweed pollen allergen extract. Dispense the enclosed Medication Guide to the patient. Keep this and all drugs out of the reach of children.
Rx only
Medicaid utilization & spend
Medicaid utilization by pack size
Medicare Part D spend CMS · PART D · 2026 (Q1)
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | ✓ Available |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | ✓ Available |